» Articles » PMID: 37871923

Prevalence and Mortality Associations of Interstitial Lung Abnormalities in Rheumatoid Arthritis Within a Multicentre Prospective Cohort of Smokers

Abstract

Objective: To investigate the prevalence and mortality impact of interstitial lung abnormalities (ILAs) in RA and non-RA comparators.

Methods: We analysed associations between ILAs, RA, and mortality in COPDGene, a multicentre prospective cohort study of current and past smokers, excluding known interstitial lung disease (ILD) or bronchiectasis. All participants had research chest high-resolution CT (HRCT) reviewed by a sequential reading method to classify ILA as present, indeterminate or absent. RA cases were identified by self-report RA and DMARD use; non-RA comparators had neither an RA diagnosis nor used DMARDs. We examined the association and mortality risk of RA and ILA using multivariable logistic regression and Cox regression.

Results: We identified 83 RA cases and 8725 non-RA comparators with HRCT performed for research purposes. ILA prevalence was 16.9% in RA cases and 5.0% in non-RA comparators. After adjusting for potential confounders, including genetics, current/past smoking and other lifestyle factors, ILAs were more common among those with RA compared with non-RA [odds ratio 4.76 (95% CI 2.54, 8.92)]. RA with ILAs or indeterminate for ILAs was associated with higher all-cause mortality compared with non-RA without ILAs [hazard ratio (HR) 3.16 (95% CI 2.11, 4.74)] and RA cases without ILA [HR 3.02 (95% CI 1.36, 6.75)].

Conclusions: In this cohort of smokers, RA was associated with ILAs and this persisted after adjustment for current/past smoking and genetic/lifestyle risk factors. RA with ILAs in smokers had a 3-fold increased all-cause mortality, emphasizing the importance of further screening and treatment strategies for preclinical ILD in RA.

Citing Articles

Treatment of rheumatoid arthritis-associated interstitial lung disease: An appraisal of the 2023 ACR/CHEST guideline.

Saavedra A, Mueller K, Kowalski E, Qian G, Bade K, Vanni K Curr Treatm Opt Rheumatol. 2025; 10(4):43-60.

PMID: 39822854 PMC: 11735032. DOI: 10.1007/s40674-024-00217-3.


Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis.

Youssef P, Ciciriello S, Tahir T, Leadbetter J, Butcher B, Calao M Rheumatol Ther. 2025; 12(1):173-202.

PMID: 39757285 PMC: 11751354. DOI: 10.1007/s40744-024-00736-4.


Impact of Sex, Serostatus, and Smoking on Risk for Rheumatoid Arthritis-Associated Interstitial Lung Disease Subtypes.

McDermott G, Hayashi K, Juge P, Gill R, Byrne S, Gagne S Arthritis Care Res (Hoboken). 2024; 77(2):185-194.

PMID: 39257341 PMC: 11772125. DOI: 10.1002/acr.25432.


Screening, diagnosis, and monitoring of interstitial lung disease in autoimmune rheumatic diseases: A narrative review.

Good S, Sparks J, Volkmann E Rev Colomb Reumatol. 2024; 31(Suppl 1):S3-S14.

PMID: 39238598 PMC: 11376317. DOI: 10.1016/j.rcreu.2023.06.002.


Air Pollution and Rheumatoid Arthritis Risk and Progression: Implications for the Mucosal Origins Hypothesis and Climate Change for RA Pathogenesis.

Bade K, Mueller K, Sparks J Curr Rheumatol Rep. 2024; 26(10):343-353.

PMID: 39093508 DOI: 10.1007/s11926-024-01160-x.


References
1.
Washko G, Lynch D, Matsuoka S, Ross J, Umeoka S, Diaz A . Identification of early interstitial lung disease in smokers from the COPDGene Study. Acad Radiol. 2009; 17(1):48-53. PMC: 2790552. DOI: 10.1016/j.acra.2009.07.016. View

2.
Putman R, Hatabu H, Araki T, Gudmundsson G, Gao W, Nishino M . Association Between Interstitial Lung Abnormalities and All-Cause Mortality. JAMA. 2016; 315(7):672-81. PMC: 4828973. DOI: 10.1001/jama.2016.0518. View

3.
Holers V, Demoruelle M, Kuhn K, Buckner J, Robinson W, Okamoto Y . Rheumatoid arthritis and the mucosal origins hypothesis: protection turns to destruction. Nat Rev Rheumatol. 2018; 14(9):542-557. PMC: 6704378. DOI: 10.1038/s41584-018-0070-0. View

4.
Hunninghake G, Hatabu H, Okajima Y, Gao W, Dupuis J, Latourelle J . MUC5B promoter polymorphism and interstitial lung abnormalities. N Engl J Med. 2013; 368(23):2192-200. PMC: 3747636. DOI: 10.1056/NEJMoa1216076. View

5.
Juge P, Solomon J, van Moorsel C, Garofoli R, Lee J, Louis-Sydney F . MUC5B promoter variant rs35705950 and rheumatoid arthritis associated interstitial lung disease survival and progression. Semin Arthritis Rheum. 2021; 51(5):996-1004. DOI: 10.1016/j.semarthrit.2021.07.002. View